---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-055781"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2021-11-01T23:59:59+00:00"
generated_at: "2026-06-28T15:50:09.684506+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q3 net loss $4.05M, cash $73.8M; RADR hits 10B datapoints, LP-184 ODD

## Summary
- Net loss $4.05M ($0.36 per share) vs $1.70M in Q3 2020; R&D expenses $2.96M up from $0.60M.
- Cash and marketable securities $73.8M as of Sep 30, 2021, up from $19.2M at Dec 31, 2020.
- RADR platform surpassed 10 billion curated oncology data points, up from 4.6B in earlier 2021.
- LP-184 received Orphan Drug Designation from FDA for pancreatic cancer and glioblastoma.
- Announced strategic collaborations with Deep Lens and Code Ocean; planning Phase 2 trial for LP-300.

## SEC filing metadata
- accession: 0001213900-21-055781
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2021-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000121390021055781/0001213900-21-055781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000121390021055781/ea149696-8k_lantern.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-055781
- JSON: https://secwatch.observer/filing/0001213900-21-055781.json
- Plain text: https://secwatch.observer/filing/0001213900-21-055781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.